Last updated: September 6, 2026
Granisetron hydrochloride is a mature, low-growth antiemetic marketed mainly as a generic injectable, oral tablet, oral solution, and transdermal patch. Its commercial value is concentrated in hospital oncology, outpatient chemotherapy, and a smaller branded transdermal segment. Generic competition has compressed prices for standard formulations, while differentiated delivery systems retain higher pricing and narrower competition.
The product has no meaningful biosimilar risk because granisetron hydrochloride is a chemically synthesized small molecule. Its principal commercial risks are generic substitution, declining use of older 5-HT3 antagonists in favor of newer antiemetic regimens, hospital purchasing pressure, and limited clinical differentiation from ondansetron and palonosetron.
What is the current market position of granisetron hydrochloride?
Granisetron hydrochloride is a selective 5-HT3 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting. FDA-approved dosage forms include injection, tablets, oral solution, and the Sancuso transdermal system, depending on product and labeling status (FDA, 2023a; FDA, 2023b).
| Market attribute |
Assessment |
| Therapeutic class |
5-HT3 receptor antagonist |
| Primary use |
Chemotherapy-induced nausea and vomiting |
| Main customers |
Hospitals, oncology clinics, specialty pharmacies |
| Standard formulations |
Injection, tablets, oral solution |
| Differentiated formulation |
Transdermal patch |
| Market maturity |
Mature |
| Generic competition |
High for conventional dosage forms |
| Biosimilar exposure |
None |
| Pricing power |
Low for injection and tablets; higher for transdermal delivery |
| Main competitors |
Ondansetron, palonosetron, dolasetron where available, and multi-drug antiemetic regimens |
| Regulatory pathway for competitors |
ANDA for conventional generics; 505(b)(2) or full NDA for differentiated delivery systems |
Granisetron remains clinically relevant where a prescriber prefers its dosing profile, where institutional protocols include it, or where a patch is useful for patients unable to tolerate oral medication. Its market position is weaker in protocols that use palonosetron because palonosetron has a longer duration of action and is widely used in moderately and highly emetogenic chemotherapy regimens.
How large is the granisetron hydrochloride market?
A reliable standalone global revenue figure for granisetron hydrochloride is not publicly reported across all manufacturers and formulations. The product is fragmented among generic suppliers, hospital contracts, distributors, and branded or licensed transdermal products.
The financial structure is therefore different from that of a single-brand drug:
- Conventional generic granisetron generates high unit volume but limited revenue per dose.
- Injectable supply is exposed to hospital tenders, shortages, contract manufacturing, and wholesaler concentration.
- Oral products face direct substitution from ondansetron and other low-cost antiemetics.
- Transdermal granisetron captures higher revenue per treatment course but addresses a narrower patient population.
- Total category revenue is likely to decline or remain broadly stable in value terms while demand persists in treatment volume.
Public company filings may disclose branded product revenue, but they generally do not provide a complete global market total for granisetron hydrochloride. This prevents a precise market-share calculation or consolidated annual revenue series.
What is the financial trajectory for granisetron hydrochloride?
The financial trajectory is mature-to-declining for standard formulations and relatively more resilient for the transdermal patch.
Conventional generic formulations
Injection and oral granisetron have limited ability to sustain price increases. Buyers can substitute among multiple approved manufacturers, and hospitals commonly use formulary contracts or group purchasing arrangements. Revenue performance depends more on supply reliability and contract retention than on clinical differentiation.
The main financial characteristics are:
- Low average selling prices.
- High sensitivity to tender losses.
- Margin pressure from active pharmaceutical ingredient and fill-finish costs.
- Periodic price increases during supply shortages.
- Limited promotional spending.
- Low switching costs for institutional buyers.
Generic revenue can increase temporarily when a competitor exits the market or when manufacturing disruptions reduce supply. Those gains are generally unstable because additional suppliers can re-enter or expand production.
Transdermal granisetron
Sancuso is the principal differentiated granisetron product in the United States. The product was approved by FDA in 2008 for prevention of nausea and vomiting associated with moderately and highly emetogenic chemotherapy, subject to the labeled treatment duration and use conditions (FDA, 2023b).
The patch has several commercial advantages:
- It avoids daily oral dosing during the treatment window.
- It can be useful for patients with difficulty swallowing or maintaining oral therapy.
- It provides a differentiated delivery system rather than another immediate-release oral product.
- It is less exposed to direct automatic substitution than a conventional tablet.
Its limitations are a smaller eligible market, higher production complexity, competition from intravenous and oral antiemetic regimens, and payer scrutiny over premium pricing. Its commercial trajectory is likely to be more stable than that of commodity generic tablets, but it remains dependent on oncology protocol adoption and reimbursement.
When does granisetron hydrochloride lose exclusivity?
The original small-molecule exclusivity for granisetron hydrochloride expired many years ago. Standard generic entry is therefore established in the United States and other major markets.
The relevant exclusivity distinction is:
| Product type |
Exclusivity position |
| Original granisetron injection |
Historical exclusivity expired |
| Original granisetron tablets |
Historical exclusivity expired |
| Generic injection and tablets |
Mature ANDA market |
| Transdermal granisetron |
Delivery-system and product-specific protection may differ from the active ingredient |
| New formulation or device |
Potentially eligible for separate patent or regulatory protection |
The expiration of active-ingredient protection does not eliminate all possible barriers. A transdermal patch can have separate patents covering adhesive composition, drug-release characteristics, matrix structure, manufacturing processes, or treatment methods. Those rights must be assessed at the product level rather than inferred from the age of the active ingredient.
What is the Orange Book status of granisetron hydrochloride?
The FDA Orange Book distinguishes between approved drug products and patent or exclusivity listings. Conventional granisetron hydrochloride products are generally positioned as generic products with no meaningful remaining new-molecule exclusivity.
For a specific product, an Orange Book review should examine:
- NDA versus ANDA status.
- Listed patents for the product.
- Pediatric exclusivity.
- New clinical investigation exclusivity.
- Patent certification history.
- Whether the listing relates to the active ingredient, formulation, method of use, or device.
The regulatory status differs between a generic tablet or injection and a branded transdermal system. A generic injectable granisetron product does not automatically establish freedom to market a transdermal product, because the patch may implicate separate formulation and delivery patents.
What patents protect granisetron hydrochloride products?
The original compound and early pharmaceutical formulations are long past their commercial exclusivity periods. Current protection, where it exists, is more likely to concern the delivery system or manufacturing process.
Potentially relevant patent categories
- Transdermal matrix and reservoir systems.
- Adhesive formulations that control drug release.
- Patch dimensions and drug loading.
- Stabilization of granisetron hydrochloride.
- Manufacturing processes for drug-in-adhesive systems.
- Methods for preventing chemotherapy-induced nausea and vomiting.
- Combination regimens involving granisetron and other antiemetics.
A patent covering granisetron hydrochloride as a chemical entity would not normally block modern generic entry because the active ingredient has been commercially available for decades. The stronger remaining barriers are product-specific claims that are difficult to design around without sacrificing delivery performance.
Which companies are challenging or competing with granisetron hydrochloride?
Competition comes from both direct granisetron suppliers and alternative antiemetic products.
| Competitor |
Competitive basis |
| Ondansetron |
Broad generic availability and low price |
| Palonosetron |
Longer duration and common use in chemotherapy protocols |
| Aprepitant and fosaprepitant |
NK1 antagonism in combination antiemetic regimens |
| Olanzapine |
Increasing use in selected chemotherapy protocols |
| Dexamethasone |
Combination backbone in many regimens |
| Other generic granisetron manufacturers |
Price and supply competition |
| Transdermal antiemetic alternatives |
Delivery convenience and adherence |
The most significant competitive threat is not another granisetron manufacturer. It is protocol substitution. Antiemetic treatment is increasingly selected as a regimen, with 5-HT3 antagonists used alongside NK1 antagonists, dexamethasone, and sometimes olanzapine. This limits the ability of any single 5-HT3 product to expand independently.
What Paragraph IV challenges and generic launch risks exist?
Paragraph IV risk is most relevant to product-specific patents covering branded transdermal granisetron or other differentiated formulations. Conventional granisetron tablets and injections already face established generic competition, so the commercial issue is less whether generic entry will occur and more whether additional entrants will intensify price erosion.
A prospective ANDA applicant for a protected formulation could use:
- Paragraph IV certification, alleging that listed patents are invalid or not infringed.
- Paragraph III certification, delaying launch until patent expiry.
- A section viii statement, carving out patented methods of use where permitted.
- A design-around formulation that avoids asserted delivery or manufacturing claims.
For the transdermal product, launch risk depends on the scope and remaining term of listed patents, the sponsor’s litigation response, and whether the generic product is substitutable under state pharmacy law. A successful first Paragraph IV challenger could obtain 180-day generic exclusivity if statutory conditions are met, although the value of that exclusivity depends on the size of the patch market and the number of competing applicants.
What litigation and settlement issues affect granisetron hydrochloride?
The major litigation exposure is formulation-specific rather than molecule-wide. Typical disputes would concern:
- Whether a patch claim covers the proposed generic adhesive system.
- Whether a method-of-use patent is properly listed.
- Whether a generic label induces infringement.
- Whether the asserted patent is enabled and adequately described.
- Whether a manufacturing process claim is infringed by an overseas supplier.
- Whether a settlement restricts the generic launch date.
The conventional injectable and tablet markets are less likely to generate high-value patent litigation because the principal composition and use rights are old. Commercial disputes are more likely to involve supply contracts, shortages, product quality, recalls, or reimbursement.
What manufacturing and intellectual-property barriers affect supply?
Manufacturing barriers are moderate for tablets and injections but higher for transdermal products.
Tablets and oral solution
Manufacturing is comparatively conventional. Key risks include API sourcing, stability, excipient compatibility, and quality-system compliance. Multiple approved sources can limit the impact of a single supplier failure.
Injection
Sterile manufacturing creates higher operational risk. A plant shutdown, contamination event, inspection finding, or shortage of sterile capacity can produce temporary pricing power for remaining suppliers. FDA shortage data and manufacturer notifications are therefore more relevant to near-term financial performance than patent status.
Transdermal patch
The patch requires control of:
- Drug crystallization.
- Adhesive performance.
- Uniform drug distribution.
- Skin adhesion over the treatment period.
- Release kinetics.
- Packaging and stability.
- Device and manufacturing consistency.
These requirements increase development costs and can slow generic entry even when the underlying active ingredient is unprotected.
How does granisetron compare with ondansetron and palonosetron?
| Factor |
Granisetron hydrochloride |
Ondansetron |
Palonosetron |
| Market age |
Mature |
Mature |
Newer than granisetron |
| Generic pressure |
High |
High |
Increasing |
| Duration of action |
Intermediate |
Shorter |
Longer |
| Main formulations |
Injection, oral, patch |
Injection, oral, orally disintegrating |
Injection, oral in selected markets |
| Price power |
Low for generics; higher for patch |
Low |
Generally higher than older generics |
| Differentiation |
Transdermal delivery |
Broad availability |
Pharmacokinetic duration |
| Main commercial risk |
Commodity erosion and protocol substitution |
Extreme price competition |
Payer pressure and generic entry |
Granisetron has a defensible niche where the transdermal route provides value. Its standard formulations have limited commercial differentiation from ondansetron.
What is the outlook for granisetron hydrochloride revenue?
The base-case outlook is stable-to-declining revenue for conventional products and modest resilience for differentiated delivery.
| Scenario |
Market effect |
Financial effect |
| Stable oncology volumes |
Continued demand for antiemetic therapy |
Flat unit demand, declining prices |
| More protocol use of palonosetron or olanzapine |
Reduced granisetron share |
Lower volume |
| Generic supplier exit |
Temporary supply-driven price increase |
Short-term revenue and margin improvement |
| New transdermal competition |
Lower patch pricing |
Reduced branded revenue |
| Hospital consolidation |
Greater purchasing leverage |
Lower generic margins |
| Manufacturing disruption |
Temporary scarcity |
Volatile revenue and pricing |
The product is unlikely to produce significant growth through molecule expansion. Any upside would come from supply shortages, improved transdermal penetration, new geographic distribution, or a licensing transaction involving a differentiated delivery system.
Key Takeaways
- Granisetron hydrochloride is a mature antiemetic with established generic competition.
- Conventional tablets, oral solution, and injection have low pricing power.
- The transdermal patch is the principal differentiated commercial opportunity.
- No biosimilar risk exists because granisetron is a small-molecule drug.
- The most important competitors are ondansetron, palonosetron, and combination antiemetic regimens.
- Patent risk is concentrated in formulation, delivery-system, manufacturing, and method-of-use claims.
- Paragraph IV risk is most relevant to generic versions of protected transdermal products.
- Financial performance depends more on hospital contracts, supply reliability, and protocol selection than on active-ingredient exclusivity.
- Public data do not support a reliable consolidated global revenue figure for all granisetron hydrochloride products.
- The likely long-term trajectory is declining value for commodity formulations and more stable value for differentiated delivery systems.
FAQs
Is granisetron hydrochloride still under patent?
The original active-ingredient exclusivity has expired. Any remaining relevant rights are more likely to cover a specific formulation, transdermal system, manufacturing process, or method of use.
Is granisetron hydrochloride interchangeable with ondansetron?
They are both 5-HT3 receptor antagonists, but interchangeability depends on the formulation, dose, indication, institutional protocol, and prescriber decision. They are not automatically interchangeable in every clinical or regulatory setting.
Can a generic company launch a granisetron patch?
A generic company can pursue an ANDA or another FDA pathway, but it must address product-specific patents, device characteristics, bioequivalence or adhesion requirements, and any listed method-of-use claims.
Does granisetron hydrochloride have biosimilar competition?
No. Biosimilars apply to biologic products. Granisetron hydrochloride is a chemically synthesized small molecule, so competing products generally enter through generic-drug pathways.
Which granisetron formulation has the strongest commercial position?
The transdermal formulation has the strongest differentiation and pricing potential. Injectable and oral formulations have greater volume but face substantially higher generic and hospital-purchasing pressure.
References
-
Cumberland Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2023a). Granisetron hydrochloride injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (2023b). Sancuso (granisetron transdermal system) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database. FDA.
-
U.S. Food and Drug Administration. (2024c). Drug shortages database. FDA.
-
National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Antiemesis. NCCN.
